56,504 Shares in Collegium Pharmaceutical, Inc. $COLL Acquired by Empowered Funds LLC

Empowered Funds LLC bought a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) during the 2nd quarter, Holdings Channel.com reports. The firm bought 56,504 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,045,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in COLL. Vident Advisory LLC increased its position in Collegium Pharmaceutical by 1.9% during the 3rd quarter. Vident Advisory LLC now owns 15,466 shares of the specialty pharmaceutical company’s stock valued at $541,000 after purchasing an additional 281 shares during the period. Quadrant Capital Group LLC lifted its position in shares of Collegium Pharmaceutical by 4.2% in the 4th quarter. Quadrant Capital Group LLC now owns 6,996 shares of the specialty pharmaceutical company’s stock worth $324,000 after purchasing an additional 282 shares during the period. Atom Investors LP boosted its stake in shares of Collegium Pharmaceutical by 5.0% in the 4th quarter. Atom Investors LP now owns 6,124 shares of the specialty pharmaceutical company’s stock valued at $284,000 after purchasing an additional 294 shares during the last quarter. Assetmark Inc. boosted its stake in shares of Collegium Pharmaceutical by 9.3% in the 1st quarter. Assetmark Inc. now owns 3,923 shares of the specialty pharmaceutical company’s stock valued at $130,000 after purchasing an additional 335 shares during the last quarter. Finally, ProShare Advisors LLC increased its position in shares of Collegium Pharmaceutical by 5.0% during the fourth quarter. ProShare Advisors LLC now owns 7,507 shares of the specialty pharmaceutical company’s stock worth $348,000 after buying an additional 356 shares during the period.

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock opened at $23.70 on Friday. The stock has a market capitalization of $771.67 million, a price-to-earnings ratio of 19.11 and a beta of 0.72. Collegium Pharmaceutical, Inc. has a 52-week low of $23.64 and a 52-week high of $50.79. The stock’s 50 day moving average price is $32.12 and its two-hundred day moving average price is $34.37. The company has a debt-to-equity ratio of 3.32, a quick ratio of 0.84 and a current ratio of 1.03.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20. The company had revenue of $199.88 million during the quarter, compared to the consensus estimate of $199.62 million. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The company’s quarterly revenue was up 6.3% on a year-over-year basis. During the same quarter last year, the firm posted $1.68 EPS. On average, equities analysts predict that Collegium Pharmaceutical, Inc. will post 6.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on COLL. Zacks Research downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Truist Financial raised shares of Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday, June 15th. Wall Street Zen downgraded Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings downgraded Collegium Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, August 11th. Finally, Needham & Company LLC lowered their price objective on Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $51.00.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.